Brighthouse FinancialBHF

Key highlights

• Actuarial review inflates profit: Reported earnings included a $314 million one-time benefit from an annual review of long-term insurance assumptions, which will not repeat. After removing these and other unusual items, the company earned $3.68 per share compared to $4.54 per share a year ago.
• Merger delays continue: The company and Aquarian Capital are discussing an extension of their merger agreement because they do not expect to receive required regulatory approvals from Delaware, New York, and Massachusetts by the current December 6, 2026 deadline. The deal is valued at $70.00 per share in cash, but there is no guarantee the parties will agree on a new date.
• Shield annuity sales steady: Sales of Shield Level Annuities, which are insurance products that protect against market losses, reached $2.1 billion. While these specific sales were strong, total annuity sales fell 12% from a year ago to $2.4 billion due to lower demand for fixed annuities.
• Investment income yield rises: The yield on investments, meaning the return the company earns on its portfolio, rose to 4.41% from 4.17% in the previous quarter. Total adjusted investment income grew to $1.31 billion, helped by higher returns from alternative investments like private equity and hedge funds.
• Capital levels remain stable: The company's estimated risk-based capital ratio, a key measure of its ability to pay future claims, was between 415% and 435%. This remains within the target range of 400% to 450% even after a significant rise in interest rates during the quarter reduced some capital values.
• Profit volatility expected ahead: Management expects net income to remain volatile because the market value of its financial hedges does not always move in sync with its required insurance reserves. This mismatch contributed to a $1.15 billion loss on derivatives this quarter, a sharp increase from the $410 million loss reported a year ago.

Our take: This was a soft quarter despite the headline earnings beat, as much of the profit came from a one-time accounting review rather than daily operations. The biggest concern for owners is the regulatory delay for the pending merger, which is now missing its original deadline. While the core Shield annuity business is still healthy, the uncertainty around the buyout price of $70.00 per share makes the long-term case harder to judge until new terms are signed.